ストックスクリーナーアプリを入手
25.22
6.23%
1.48
アフターアワーズ：
25.15
-0.07
-0.28%
前日終値:
$23.74
開ける：
$23.64
24時間の取引高:
72,582
Relative Volume:
1.11
時価総額：
$840.27M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-5.90%
1か月 パフォーマンス:
-13.42%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$23.64
$25.96
1週間の範囲:
$22.41
$27.20
52週間の値動き範囲:
$22.41
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Compare SGP vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
25.22 | 790.96M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2026-03-03 | 開始されました | Citigroup | Buy |
| 2026-03-03 | 開始されました | Jefferies | Buy |
| 2026-03-03 | 開始されました | Leerink Partners | Outperform |
| 2026-03-03 | 開始されました | Stifel | Buy |
Spyglass Pharma Inc (SGP) 最新ニュース
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P TMI Index - marketscreener.com
SGP Stock Price, News & Analysis - Stock Titan
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com Australia
SpyGlass Pharma reports positive 12-month glaucoma device trial data By Investing.com - Investing.com India
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System - The Manila Times
Spyglass Pharma surges on public debut; Agomab falls - MSN
Spyglass Pharma (NASDAQ:SGP) Upgraded at Zacks Research - Defense World
Polsinelli Advises SpyGlass Pharma on Intellectual Property Matters in Initial Public Offering - The National Law Review
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Bitget
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at Citigroup - Defense World
Latest SGP ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Stifel Initiates Coverage of SpyGlass Pharma (SGP) with Buy Recommendation - Nasdaq
Leerink initiates SpyGlass Pharma stock with Outperform rating By Investing.com - Investing.com Canada
Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus - MarketBeat
Jefferies initiates SpyGlass Pharma stock with buy rating on glaucoma drug - Investing.com Canada
Leerink Initiates SpyGlass Pharma at Outperform With $42 Price Target - marketscreener.com
Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target - marketscreener.com
Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential - Investing.com Canada
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
SGP SEC FilingsSpyGlass Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
SpyGlass Pharma (SGP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SGP News Today | Why did Spyglass Pharma stock go down today? $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Trends and Sentiment 2026 $SGP - MarketBeat
Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders - Yahoo Finance
New Enterprise Associates 17, L.P. Increases Stake in SpyGlass P - GuruFocus
NEA 17 (SGP) converts preferred and buys 937,500 SpyGlass Pharma shares - Stock Titan
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma (Nasdaq: SGP) closes $172.5M IPO at $16 per share - Stock Titan
SpyGlass Pharma closes $172.5 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
SpyGlass Pharma closes $172.5 million IPO on NASDAQ - Investing.com South Africa
SpyGlass Pharma Announces Closing of Initial Public - GlobeNewswire
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO - TipRanks
SpyGlass Pharma Raises $150 Million in Initial Public Offering - VisionMonday
SpyGlass Pharma, Inc. (SGP) Eps Diluted (TTM) - Zacks Investment Research
SpyGlass Pharma, Inc (SGP) Stock Price Today & Analysis - Gotrade
SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One - Smartkarma
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SpyGlass Pharma, Developer of Long-Acting Ocular Drug-Delivery Implants for Glaucoma and Other Chronic Eye Conditions, Files for Nasdaq Global Select Market IPO - TradingView
Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO - Bloomberg.com
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts - Intellectia AI
Spyglass Pharma shares surge 50% in Nasdaq debut By Investing.com - Investing.com Canada
Spyglass Pharma Inc (SGP) 財務データ
Spyglass Pharma Inc (SGP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):